DK1786785T3 - Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere - Google Patents

Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere

Info

Publication number
DK1786785T3
DK1786785T3 DK05779735.9T DK05779735T DK1786785T3 DK 1786785 T3 DK1786785 T3 DK 1786785T3 DK 05779735 T DK05779735 T DK 05779735T DK 1786785 T3 DK1786785 T3 DK 1786785T3
Authority
DK
Denmark
Prior art keywords
protein kinase
kinase inhibitors
enantiomerically pure
heteroaryl compounds
pure amino
Prior art date
Application number
DK05779735.9T
Other languages
English (en)
Inventor
Jingrong J Cui
Lee A Funk
Lei Jia
Pei-Pei Kung
Jerry J Meng
Mitchell D Nambu
Mason A Pairish
Shen-Hong
M B Tran-Dube
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35967909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1786785(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1786785T3 publication Critical patent/DK1786785T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
DK05779735.9T 2004-08-26 2005-08-15 Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere DK1786785T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60508604P 2004-08-26 2004-08-26
PCT/IB2005/002837 WO2006021884A2 (en) 2004-08-26 2005-08-15 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1786785T3 true DK1786785T3 (da) 2010-05-31

Family

ID=35967909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05779735.9T DK1786785T3 (da) 2004-08-26 2005-08-15 Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere

Country Status (46)

Country Link
US (4) US7858643B2 (da)
EP (1) EP1786785B9 (da)
JP (1) JP4242911B2 (da)
KR (1) KR100859891B1 (da)
CN (1) CN101023064B (da)
AP (1) AP2373A (da)
AR (1) AR050788A1 (da)
AT (1) ATE463486T1 (da)
AU (1) AU2005276135B2 (da)
BR (2) BRPI0513915A (da)
CA (1) CA2578066C (da)
CR (1) CR8860A (da)
CY (2) CY1110044T1 (da)
DE (1) DE602005020465D1 (da)
DK (1) DK1786785T3 (da)
EA (1) EA013678B1 (da)
EC (1) ECSP077276A (da)
ES (1) ES2341351T3 (da)
FR (1) FR13C0015I2 (da)
GE (1) GEP20104906B (da)
GT (1) GT200500225A (da)
HK (1) HK1105414A1 (da)
HN (1) HN2005000476A (da)
HR (1) HRP20100298T1 (da)
IL (1) IL181384A (da)
LU (1) LU92155I2 (da)
MA (1) MA28828B1 (da)
ME (1) ME01788B (da)
MX (1) MX2007002312A (da)
MY (1) MY145177A (da)
NI (1) NI200700057A (da)
NL (1) NL1029799C2 (da)
NO (2) NO333231B1 (da)
NZ (1) NZ552866A (da)
PA (1) PA8643301A1 (da)
PE (1) PE20060501A1 (da)
PL (1) PL1786785T3 (da)
PT (1) PT1786785E (da)
RS (1) RS51362B (da)
SI (1) SI1786785T1 (da)
TN (1) TNSN07070A1 (da)
TW (1) TWI358406B (da)
UA (1) UA87153C2 (da)
UY (1) UY29081A1 (da)
WO (1) WO2006021884A2 (da)
ZA (1) ZA200700127B (da)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401330T3 (es) * 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
NZ552946A (en) * 2004-08-26 2010-09-30 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
CN101023064B (zh) * 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
CA2632286C (en) * 2005-12-05 2011-11-15 Pfizer Products Inc. Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer
DK1963302T3 (da) * 2005-12-05 2013-04-02 Pfizer Prod Inc Polymorfer af en C-MET/HGFR-inhibitor
CA2646701A1 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP3266867A1 (en) 2006-04-14 2018-01-10 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
WO2008021781A1 (en) * 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8551995B2 (en) * 2007-01-19 2013-10-08 Xcovery Holding Company, Llc Kinase inhibitor compounds
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
JP5973131B2 (ja) 2007-09-13 2016-08-23 コデクシス， インコーポレイテッド アセトフェノンの還元のためのケトレダクターゼポリペプチド
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
NZ589622A (en) 2008-05-21 2012-10-26 Incyte Corp Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
JP5753093B2 (ja) 2008-12-19 2015-07-22 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体
EP3354643B1 (en) 2009-05-01 2020-10-28 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US9126931B2 (en) * 2009-06-10 2015-09-08 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
CA2788398C (en) 2010-02-03 2018-02-27 Incyte Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
CA2796967C (en) * 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
CN103228651A (zh) 2010-05-12 2013-07-31 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013529200A (ja) * 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
EP3698788A1 (en) 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
JP5965923B2 (ja) * 2011-02-24 2016-08-10 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド プロテインキナーゼ阻害剤としてのリン含有化合物
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
AU2012223281A1 (en) * 2011-03-03 2013-09-19 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN102850328B (zh) * 2011-07-01 2014-12-24 苏州东南药业股份有限公司 吡啶类化合物、其制备方法、包含该化合物的药物组合物及其用途
EP2739284A1 (en) 2011-08-02 2014-06-11 Pfizer Inc Crizotinib for use in the treatment of cancer
EP2758387A4 (en) * 2011-09-21 2015-03-11 Teligene Ltd Pyridine compounds as kinase inhibitors
IN2014CN02501A (da) 2011-09-30 2015-06-26 Vertex Pharma
KR102184246B1 (ko) 2011-09-30 2020-12-01 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물의 제조 방법
CN103204844A (zh) * 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
CN104703598A (zh) 2012-01-20 2015-06-10 奥克塞拉有限公司 用于疾病治疗的取代的杂环化合物
EP2620140A1 (en) 2012-01-26 2013-07-31 ratiopharm GmbH Crizotinib containing compositions
PL2822953T3 (pl) 2012-03-06 2017-07-31 Pfizer Inc. Makrocykliczne pochodne do leczenia chorób proliferacyjnych
US9815831B2 (en) 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
AU2013243291B2 (en) 2012-04-05 2018-02-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
CN103373986B (zh) * 2012-04-22 2016-10-05 东南大学 克里唑替尼前药及其制备方法与用途
CN103387535B (zh) * 2012-05-10 2016-06-01 广东东阳光药业有限公司 取代的炔基吡啶化合物及其使用方法和用途
CN103420987B (zh) * 2012-05-15 2015-11-25 上海医药工业研究院 吡啶衍生物及其制备方法
CN103420906B (zh) * 2012-05-21 2015-09-09 南京圣和药业股份有限公司 新型酪氨酸蛋白激酶抑制剂
WO2013181251A1 (en) 2012-05-29 2013-12-05 Ratiopharm Gmbh Crizotinib hydrochloride salt in crystalline
CN103509008A (zh) * 2012-06-22 2014-01-15 康瑟特制药公司 吡唑取代的氨基-杂芳基化合物的衍生物
WO2013192512A1 (en) * 2012-06-22 2013-12-27 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
US9446039B2 (en) 2012-08-27 2016-09-20 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Aminoheteroaryl compounds as MTH1 inhibitors
US9651555B2 (en) 2012-09-24 2017-05-16 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
CA2885722C (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha Ret inhibitor
DK2904406T3 (da) 2012-10-04 2018-06-18 Vertex Pharma Fremgangsmåde til bestemmelse af den ved atr-inhibition optrædende, forøgede dna-beskadigelse
WO2014081816A1 (en) * 2012-11-21 2014-05-30 Concert Pharmaceuticals, Inc. Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
CN104016979B (zh) * 2012-11-23 2017-05-03 广东东阳光药业有限公司 取代的环化合物及其使用方法和用途
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
CA2896187A1 (en) * 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
ES2716617T3 (es) * 2013-02-02 2019-06-13 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhibidor de proteína quinasa de 2-aminopiridina sustituida
WO2014139391A1 (en) * 2013-03-11 2014-09-18 Teligene Ltd Substituted pyridine compounds as kinases inhibitors
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
WO2014203177A1 (en) * 2013-06-18 2014-12-24 Shilpa Medicare Limited Amorphous (r) -3- [1- (2, 6-dichloro-3-fluorophenyl) methoxy] -5- [1- (piperidin-4- yl) -1h-pyrazol-4-yl] pyridin-2-amine
CN104650049B (zh) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
WO2015034729A1 (en) * 2013-09-05 2015-03-12 Calitor Sciences, Llc Substituted pyridine compounds and methods of use
WO2015036898A2 (en) * 2013-09-10 2015-03-19 Shilpa Medicare Limited Novel salts of crizotinib and their preparation
CA2924545C (en) * 2013-09-20 2022-12-06 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN103755627B (zh) * 2014-01-09 2016-02-17 定陶县友帮化工有限公司 2-氨基-3-羟基-5-氯吡啶的合成方法
AU2015211119B2 (en) * 2014-01-29 2019-05-30 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
JP6247992B2 (ja) * 2014-04-17 2017-12-13 株式会社ダイセル ハロゲン化合物の製造方法
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
SG11201607623XA (en) 2014-04-25 2016-11-29 Chugai Pharmaceutical Co Ltd Preparation containing tetracyclic compound at high dose
ES2762641T3 (es) 2014-07-31 2020-05-25 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhibidores de proteína quinasa de 2-aminopiridina sustituida con piridina
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CN105348265A (zh) * 2014-08-19 2016-02-24 蔡苹 一种具有ALK和c-Met抑制活性的2,4-二取代杂环三氮唑类化合物的制备和应用
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
CN105820113B (zh) * 2015-01-07 2018-04-20 爱技特科技（北京）有限公司 一种克唑替尼手性中间体的制备方法
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
CN104693184A (zh) * 2015-03-17 2015-06-10 安润医药科技（苏州）有限公司 克唑替尼的合成方法
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
EP3376870B1 (en) * 2015-11-17 2021-08-11 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
AU2017266951B2 (en) 2016-05-20 2021-05-27 Biohaven Pharmaceutical Holding Company Ltd. Use of Glutamate modulating agents with Immunotherapies to treat cancer
CN106083708A (zh) * 2016-06-30 2016-11-09 浙江大学 含2‑吡啶酮环侧链的2‑氨基吡啶衍生物及制备和应用
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
KR20230150408A (ko) 2016-12-22 2023-10-30 암젠 인크 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
CN106831720B (zh) * 2017-01-21 2019-04-16 河北科技大学 双-4-(1h-吡唑-1-基)哌啶-1-甲酸叔丁酯的合成方法及其应用
KR20190135027A (ko) 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI731264B (zh) 2017-09-08 2021-06-21 美商安進公司 Kras g12c抑制劑以及其使用方法
JP6635999B2 (ja) * 2017-10-13 2020-01-29 株式会社ダイセル カリウム塩の製造方法、及びカリウム塩
CN108191833A (zh) * 2018-01-17 2018-06-22 浙江树人学院 克唑替尼衍生物及其制备方法和应用
CN110396088B (zh) * 2018-04-25 2024-03-12 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂、制备方法及其应用
WO2019206049A1 (en) * 2018-04-25 2019-10-31 Zhuhai Yufan Biotechnologies Co., Ltd Hpk1 inhibitors, preparation method and application thereof
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7266043B2 (ja) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
JP7360396B2 (ja) 2018-06-01 2023-10-12 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
EP3848361A4 (en) 2018-09-04 2022-06-15 Chugai Seiyaku Kabushiki Kaisha TETRACYCLIC COMPOUND PRODUCTION PROCESS
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA55136A (fr) 2018-11-19 2022-02-23 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2021007158A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
BR112021011989A2 (pt) 2018-12-20 2021-09-08 Amgen Inc. Inibidores de kif18a
MX2021007157A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
CA3130083A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
JP7092935B2 (ja) 2019-05-21 2022-06-28 アムジエン・インコーポレーテツド 固体形態
US20220281843A1 (en) 2019-08-02 2022-09-08 Amgen Inc. Kif18a inhibitors
EP4007638A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
JP2022552873A (ja) 2019-10-24 2022-12-20 アムジエン・インコーポレーテツド がんの治療におけるｋｒａｓ ｇ１２ｃ及びｋｒａｓ ｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体
MX2022005053A (es) 2019-10-28 2022-05-18 Merck Sharp & Dohme Llc Inhibidores de peque?as moleculas de mutante g12c de kras.
JP2023515235A (ja) 2019-10-31 2023-04-12 大鵬薬品工業株式会社 ４－アミノブタ－２－エンアミド誘導体及びその塩
CA3159559A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
JP2023500328A (ja) 2019-11-08 2023-01-05 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Síntese melhorada de composto inibidor de kras g12c
TW202132271A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
JP2023505100A (ja) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド 共有ｒａｓ阻害剤及びその使用
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤投薬およびがんを処置する方法
WO2021196655A1 (zh) * 2020-04-03 2021-10-07 中国药科大学 含苯并咪唑结构的化合物及其制备方法与用途
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
EP4139299A1 (en) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022014640A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
CN114437058A (zh) * 2020-10-30 2022-05-06 珠海宇繁生物科技有限责任公司 氘代hpk1激酶抑制剂及其制备方法和应用
EP4267250A1 (en) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
BR112023022819A2 (pt) 2021-05-05 2024-01-16 Revolution Medicines Inc Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN114767676B (zh) * 2022-04-22 2024-04-19 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB129611A (en) 1919-04-15 1919-07-17 John Norman Riddell Hannam Improvements in Stropping or Sharpening Devices for Safety Razor Blades.
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
AU2710597A (en) 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
DE19628569A1 (de) 1996-07-16 1998-01-22 Bayer Ag Substituierte N-(5-Isothiazolyl)-thioamide
DE69712496T2 (de) 1996-07-18 2002-08-29 Pfizer Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
PT950059E (pt) 1997-01-06 2004-10-29 Pfizer Derivados de sulfona ciclicos
US6303636B1 (en) 1997-02-03 2001-10-16 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
BR9807678A (pt) 1997-02-11 2000-02-15 Pfizer Derivados de ácidos arilsulfonil-hidroxâmicos
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2299355C (en) * 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
JP2001522853A (ja) 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
DE69917124T2 (de) 1998-04-10 2005-05-12 Pfizer Products Inc., Groton Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
WO1999061422A1 (en) 1998-05-29 1999-12-02 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP3494409B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
PL346426A1 (en) 1998-08-27 2002-02-11 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CA2356748A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
IL144307A0 (en) 1999-02-11 2002-05-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
US6511993B1 (en) * 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ATE369359T1 (de) * 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US6844357B2 (en) 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2004004720A1 (en) 2002-07-03 2004-01-15 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CN1777427A (zh) * 2003-02-26 2006-05-24 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
ES2401330T3 (es) * 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
CA2578298A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates
JP2008510792A (ja) * 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
NZ552946A (en) * 2004-08-26 2010-09-30 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
CN101023064B (zh) * 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
CA2632286C (en) * 2005-12-05 2011-11-15 Pfizer Products Inc. Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer
DK1963302T3 (da) * 2005-12-05 2013-04-02 Pfizer Prod Inc Polymorfer af en C-MET/HGFR-inhibitor

Also Published As

Publication number Publication date
NZ552866A (en) 2010-06-25
PA8643301A1 (es) 2006-07-03
EA200700352A1 (ru) 2007-08-31
PE20060501A1 (es) 2006-06-28
IL181384A0 (en) 2007-07-04
NL1029799A1 (nl) 2006-02-28
EP1786785B1 (en) 2010-04-07
NO333231B1 (no) 2013-04-15
US8785632B2 (en) 2014-07-22
AU2005276135A1 (en) 2006-03-02
KR100859891B1 (ko) 2008-09-23
AP2373A (en) 2012-03-07
CY2013014I2 (el) 2015-08-05
HK1105414A1 (en) 2008-02-15
LU92155I9 (da) 2019-01-04
NO20071290L (no) 2007-05-29
ATE463486T1 (de) 2010-04-15
UY29081A1 (es) 2006-03-31
EA013678B1 (ru) 2010-06-30
US20100324061A1 (en) 2010-12-23
HRP20100298T1 (hr) 2010-06-30
CN101023064A (zh) 2007-08-22
MY145177A (en) 2011-12-30
CA2578066A1 (en) 2006-03-02
CY1110044T1 (el) 2015-01-14
FR13C0015I2 (fr) 2013-08-16
PL1786785T3 (pl) 2010-08-31
UA87153C2 (ru) 2009-06-25
CA2578066E (en) 2006-03-02
FR13C0015I1 (da) 2013-04-12
CN101023064B (zh) 2011-02-16
US20120263706A1 (en) 2012-10-18
US20060046991A1 (en) 2006-03-02
WO2006021884A2 (en) 2006-03-02
NI200700057A (es) 2008-03-07
KR20070038562A (ko) 2007-04-10
CR8860A (es) 2007-07-24
WO2006021884A3 (en) 2006-06-22
DE602005020465D1 (de) 2010-05-20
AR050788A1 (es) 2006-11-22
GT200500225A (es) 2006-03-21
ES2341351T3 (es) 2010-06-18
IL181384A (en) 2012-08-30
MX2007002312A (es) 2007-04-16
ECSP077276A (es) 2007-03-29
ME01788B (me) 2011-02-28
JP4242911B2 (ja) 2009-03-25
TW200621715A (en) 2006-07-01
MA28828B1 (fr) 2007-08-01
EP1786785A2 (en) 2007-05-23
HN2005000476A (es) 2009-12-07
NO2013008I1 (no) 2013-04-29
CY2013014I1 (el) 2015-08-05
ZA200700127B (en) 2008-08-27
BRPI0513915A (pt) 2008-05-20
AU2005276135B2 (en) 2011-04-28
NL1029799C2 (nl) 2006-10-17
US7858643B2 (en) 2010-12-28
GEP20104906B (en) 2010-02-25
AP2007003888A0 (en) 2007-02-28
SI1786785T1 (sl) 2010-07-30
ES2341351T9 (es) 2013-07-23
NO2013008I2 (no) 2013-10-21
TWI358406B (en) 2012-02-21
RS51362B (en) 2011-02-28
EP1786785B9 (en) 2013-05-22
CA2578066C (en) 2011-10-11
US20140288086A1 (en) 2014-09-25
PT1786785E (pt) 2010-05-21
TNSN07070A1 (fr) 2008-06-02
JP2008510790A (ja) 2008-04-10
BR122020017756B1 (pt) 2022-02-15
LU92155I2 (fr) 2013-04-22

Similar Documents

Publication Publication Date Title
DK1786785T3 (da) Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
DK1784396T3 (da) Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
DK2476667T3 (da) Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
DK1881976T3 (da) Substituerede amidderivater som proteinkinaseinhibitorer
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1711481T4 (da) Krystallinsk monohydrat som kinaseinhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1699797T3 (da) Pyrrolotriazinforbindelser som kinasehæmmere
DK1664043T3 (da) Sammensætninger egnede som inhibitorer af proteinkinaser
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1778686T3 (da) Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK1811998T3 (da) Triazoler anvendelige som inhibitorer af proteinkinaser
DK2039685T3 (da) Heterobicycliske forbindelser som P38-inhibitorer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
NO20082514L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DK1937671T3 (da) Benzimidazolthiophenforbindelser som PLK-inhibitorer
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
DK1658292T3 (da) Triazologyrimidinderivater som glycogensynthasekinase 3 - inhibitorer
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer